Regentis Biomaterials Ltd. (RGNT) — RQD Stock Rating Cockpit

The Roarable RQD score is 31, graded E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." Per the Roarable RQD rating, the five pillars score as follows:

• Fundamental Cash Engine: 8 / 20. The pillar reflects ROIC of -35% and FCF yield of -14.39%. For a prospective investor, this means the business is currently not converting capital into operating returns or free cash flow, so any upside case must rest on a future turn in profitability rather than present cash generation.
• Whale 13F Flow: 3 / 20. Institutional accumulation and options positioning scored low. Investors should note that the source data contains no holder detail (see Analyst View section), so this low score reflects weak institutional signal rather than a detailed holdings analysis.
• Insider Conviction: 3 / 20. SEC Form 4 and Congressional PTR cluster flow scored low, indicating limited insider-side conviction in the source data.
• Macro Regime Fit: 7 / 20. Beta is 1.0, and the score reflects sector sensitivity. A beta of 1.0 means the stock is assessed as moving in line with the broad market, offering no defensive cushion or amplified upside from the macro factor alone.
• Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The weak Piotroski reading is the most significant forensic flag and is consistent with deteriorating fundamentals.

Taken together, the score indicates that the upside drivers available to a prospective investor are limited to a possible reversal in profitability or a shift in institutional sentiment, while the valuation tradeoff is steep: at a $9.6M market cap, the equity is small and illiquid relative to the operating losses reported. The rating is an analytical assessment, not personalized advice.

Regentis Biomaterials Ltd. (RGNT) is a NYSE-listed issuer classified in the Health Care sector and the Industrial Specialties industry, per the profile section. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each period shown in the SEC financials, so the source does not establish how the company generates income. Market capitalization is listed as $9.6M.

Per the SEC financials, FY 2025 shows an operating loss of $-7.0M and a net loss of $-13.6M, while FY 2024 is the only reported period with positive net income ($4.8M). Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Debt/Equity is 0.5, and FY 2025 cash is $7.4M.

Per the recent news wire, the items are:

• A Yahoo Finance report (GREEN, CATALYST) on strong surgeon interest in GelrinC at the 8th ICRS Summit in Portugal, the most constructive item in the feed.
• A Moomoo report (YELLOW, MARKET WIRE) and several Benzinga and Traders Union items (YELLOW, MARKET WIRE) covering market action and price forecasts, which carry no fundamental detail.
• A report describing shares slipping 0.67% to $1.48 (YELLOW, MARKET WIRE), a price level above the current $1.36 quote.

Risk watch items: the news wire contains no earnings, financing, or regulatory disclosures. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no proprietary signal is available to corroborate the catalyst.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. No upstream suppliers, downstream customers, or sector correlations are identified in the source data. A prospective investor should therefore note that second-order ripple effects cannot be mapped from the available sources; any sector read-through would require information not present here.

• What products does Regentis sell, and what is the basis for the $0.0M reported revenue in each period?
• What is the company's cash runway given FY 2025 cash of $7.4M against a net loss of $-13.6M?
• What is the debt position, since debt is N/A for each period and only a Debt/Equity ratio of 0.5 is given?
• What drove the $4.8M net income in FY 2024 after losses in the other two periods?
• Does the GelrinC surgeon-interest catalyst translate into revenue or regulatory milestones?